Bring CLARITY to Temporal Lobe Epilepsy: 3D Visualization of p-Tau(Ser262) and 14-3-3 Zeta
International Journal of Biomedical Science and Engineering
Volume 5, Issue 6, December 2017, Pages: 63-67
Received: Dec. 5, 2017;
Published: Dec. 6, 2017
Views 1256 Downloads 46
Qingqin Wu, College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
Honghong Song, College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
Juan Feng, College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
Yang Xia, College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
Dezhong Yao, College of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
CLARITY is one new technology which allows the brain tissue become transparent. It has successfully been combined with immunofluorescence staining to achieve the 3D visualization of some molecules or neuronal cells in some disease brains. The temporal lobe epilepsy (TLE) is one neuronal disease which is characterized by the sprouting of the massy fibers (MSF). Previous study has showed that MSF could be affected by the phosphorylation at site-262 of microtubule association protein Tau (p-tau (Ser262)). However, in TLE little useful information was reported concerning the 3D architecture of p-tau (Ser262) and its relationship with 14-3-3 zeta that regulated the phosphorylation of Tau in AD disease. In this paper, pilocarpine-induced epilepsy model was established and identified by Timm-staining. Double immunofluorescent staining results showed that the development of TLE gave rise to the colocalization of p-tau (Ser262) and 14-3-3 zeta protein in CA1 and CA3 zone in hippocampi. The mm-thick brain sections were passively clarified, and 3D reconstruction imaging of the immunofluorescent staining showed that p-tau (Ser262) was diverse cluster-like shape. These results proved that CLARITY could be used to study TLE, in which the 3D morphologic changes of p-tau (Ser262) and the role of 14-3-3 zeta in the regulation of Tau needed to be further investigated.
Bring CLARITY to Temporal Lobe Epilepsy: 3D Visualization of p-Tau(Ser262) and 14-3-3 Zeta, International Journal of Biomedical Science and Engineering.
Vol. 5, No. 6,
2017, pp. 63-67.
Chung K, Wallace J, Kim SY, et al. Structural and molecular interrogation of intact biological systems. Nature, 2013, 497(7449): 332- 337
Dodt HU, Leischner U, Schierloh A, et al. Ultramicroscopy: three-dimensional visualization of neuronal networks in the whole mouse brain. Nat Methods, 2007, 4(4): 331-336
Ertürk A1, Becker K, Jährling N, et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO. Nat Protoc, 2012, 7(11): 1983-1995.
Hama H, Kurokawa H, Kawano H, et al. Sca/e: a chemical approach for fluorescence imaging and reconstruction of transparent mouse Brain. Nat Neurosci, 2011, 14(11): 1481-1488.
Ke MT, Fujimoto S, Imai T. See DB: a simple and morphology-preserving optical clearing agent for neuronal circuit reconstruction. Nat Neurosci. 2013, 16(8): 1154-1161.
Susaki EA, Tainaka K, Perrin D, Whole-brain imaging with single-cell resolution using chemical cocktails and computational analysis. Cell. 2014, 157(3): 726-739.
Tomer R, Ye L, Hsueh B, et al. Advanced CLARITY for rapid and high-resolution imaging of intact tissues. Nat Protoc, 2014, 9(7): 1682-1697
Lee H, Park JH, Seo I, et al. Improved application of the electrophoretic tissue clearing technology, CLARITY, to intact solid organs including brain, pancreas, liver, kidney, lung, and intestine. BMC Dev Biol., 2014,14:48. doi: 10.1186/s12861-014-0048-3
Bastrup J, Larson PH. Optimized CLARITY technique detects reduced parvalbumin density in a genetic model of schizophrenia. Journal of neuroscience methods, 2017, 283: 23-32
Deisseroth K. Optical and chemical discoveries recognized for impact on biology and psychiatry. EMBO Reports, 2017, 18(6): 859-860
Milgroom A, Ralston E. Clearing skeletal muscle with CLARITY for light microscopy imaging. Cell Biology International, 2016, 40(4): 478-483
Muzumdar MD, Dorans KJ, Chung KM, et al. Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nature Communications, 2016, 7: 12685.
Ding Y, Lee J, Ma J, et al. Light-sheet fluorescence imaging to localize cardiac lineage and protein distribution. Scientific Reports, 2017, 7: 42209. doi: 10.1038/srep42209
Leuze C，Aswendt M, Ferenczi E, et al. The separate effects of lipids and proteins on brain MRI contrast revealed through tissue clearing. Neuro Image, 2017, 156: 412-422
Syed AM, Wilhelm S, Glancy DR. Three-dimensional optical mapping of nanoparticle distribution in intact tissues. ACS Nano, 2016, 10(5): 5468-5478
Spence RD, Kurth F, Itoh N, et al. Bringing CLARITY to gray matter atrophy. Neuroimage., 2014, 101: 625-632.
Ando K, Laborde Q, Lazar A, et al. Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D. Acta Neuropathol., 2014, 28(3): 457-459.
Liu AK, Hurry ME, Ng OT, et al. Bringing CLARITY to the human brain: visualization of Lewy pathology in three dimensions [J]. Neuropathol Appl Neurobiol, 2016, 42(6): 573-587.
Umahara T, Uchihara T, Tsuchiya K, et al. 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol. 2004, 108(4):279-286. b) Sluchanko NN, Seit-Nebi AS, Gusev NB. Effect of phosphorylation on interaction of human tau protein with 14-3-3zeta. Biochem Biophys Res Commun. 2009, 379(4): 990-994.
Qureshi HY, Li T, MacDonald R, et al. Interaction of 14-3-3 zeta with microtubule-associated protein tau within Alzheimer's disease neurofibrillary tangles. Biochemistry. 2013, 52(37):6445-6455.
Glien M, Brandt C, Potschka H, et al. Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy [J]. Epilepsy Res, 2001,46(2): 111-119.